Dungeons, Dragons & Diagnosing Startup Challenges
Explore the unusual parallel between facilitating team collaboration to solve problems in fast-paced startups and role-playing games.
Something Old, Something New: What is a 505(b)2?
We explore the 505(b)2 pathway for expedited approval of previously-approved active drug ingredients with new formulations.
The FDA Could Approve Almost Any Drug (But It Won’t Approve That)
We discuss the role of the FDA in the drug approval process and their recent approval of the controversial Alzheimer’s drug, Aduhelm.
Three Drug Ideas that Deserve Redemption
We discuss three life science ideas that struggled on the market, but whose potential impact warrant a second look.
Good Ideas Gone Bad: The (Old & New) Worst Drug Launch In History
We discuss how approved drugs can fail on the market through a case examination of Exubera® and Aduhelm®.
Three Types of Successful Startup Leaders
We examine the three key archetypes and attributes of startup executives that are thrilling to work with and a privilege to work for.
Whitepaper: Five Steps to Avoid Startup Fraud
We discuss how innovative life science startups can avoid fraud, following the conviction of Theranos founder & CEO, Elizabeth Holmes.
Finding Fantastic Founder Fit
We break down ‘Founder Fit’ into three distinct phenomenon that influence your team’s communication, dynamic, and funding.
Pfizer: Erecting a New Brand Identity
We examine the aftermath and cost of Pfizer’s major rebranding effort – and discuss where the pharmaceutical giant intends to go from here.